The Glioma-IRE project − Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach

Table 3 Median survival time in subgroups with the most frequent mutations

Gene mutatation	N° patients	Median survival time (months)	95% Confidence interval
Total-SNV	38	149	60–238
IDH1-SNV	20	194	135–253
EGFR-SNV	8	19	9–28
PIK3CA-SNV	8	194	not evaluable
Total -CNV	35	20	18–22
EGFR-CNV	25	19	17.21
CDK4-CNV	8	19	0–39
Total-Fusion	21	20	17–22
EGFR-fusion	17	19	15–22

ISSN: 1479-5876